人EFTUD2基因靶向小分子化合物筛选细胞模型的建立*

doi:10.3969/j.issn.1672-5069.2021.04.005

实用肝脏病杂志 ›› 2021, Vol. 24 ›› Issue (4): 472-475.doi: 10.3969/j.issn.1672-5069.2021.04.005

人EFTUD2基因靶向小分子化合物筛选细胞模型的建立^*

田安然, 徐瑞瑞, 胡平平, 李毓雯, 朱传龙

210029 南京市南京医科大学第一附属医院感染病科(田安然,徐瑞瑞,胡平平,朱传龙);儿科(李毓雯)

收稿日期:2020-11-11 发布日期:2021-07-13
通讯作者: 朱传龙,E-mail:zhuchuanlong@jsph.org.cn
作者简介:田安然,女,26 岁,硕士研究生。主要从事病毒性肝炎防治研究
基金资助:
^*国家自然科学基金资助项目(编号:81770591/81800778)

Establishment of a cell model for screening human EFTUD2 gene-targeting small molecule compounds

Tian Anran, Xu Ruirui, Hu Pingping, et al

Department of Infectious Disease,First Affiliated Hospital,Nanjing Medical University,Nanjing 210029,Jiangsu Province,China

Received:2020-11-11 Published:2021-07-13

摘要/Abstract

摘要： 目的体外建立一个以荧光素酶为报告基因,靶向人EFTUD2基因的化合物筛选细胞模型。方法应用限制性内切酶双酶切LV6载体,将人EFTUD2pro-0.5kb启动子和荧光素酶报告基因的融合片段重组入LV6慢病毒载体。以重组慢病毒感染HepG2细胞,采用嘌呤霉素筛选和有限稀释法获得Epro-LUC-HepG2细胞株。利用荧光素酶报告基因系统挑选最佳单克隆细胞株并扩大培养。结果准确构建了LV6-Epro0.5-LUC慢病毒载体,并成功筛选出可稳定表达荧光素酶的Epro-LUC-HepG2单克隆细胞株。根据荧光素酶报告基因检测结果,挑选了最佳克隆株细胞,被命名为Epro-LUC-HepG2细胞。结论我们成功构建了以人EFTUD2基因为靶点的Epro-LUC-HepG2细胞化合物筛选模型,有助于后续筛选新型靶向免疫调节药物。

关键词: 细胞模型, EFTUD2, 慢病毒载体, 药物筛选, 体外

Abstract: Objective This paper aimed to establish a cell model with luciferase as reporter gene for screening human EFTUD2 gene-targeting compounds. Methods After double-digestion of LV6 lentivirus vector by restrictive enzymes, the target fragment was recombined into the LV6 lentivirus vector.The HepG2 cells were further infected with the recombinant lentivirus, and the Epro-LUC-HepG2 cell line was obtained by puromycin screening and limited dilution. By using the luciferase reporter gene system, we select the best single clone cell lines and expand the culture. Results The LV6-Epro0.5-LUC lentivirus vector was successfully constructed, and the Epro-LUC-HepG2 monoclonal cell lines expressing luciferase was successfully screened by lentivirus transfection and puromycin selection. According to the results of luciferase reporter gene detection, the best monoclonal cells were selected and named as Epro-LUC-HepG2 cells. Conclusion The Epro-LUC-HepG2 cells, a compounds screening model of targeting human EFTUD2 gene, is successfully constructed, which laid a hope for further screening of new targeted immunoregulatory agents.

Key words: Cell model, EFTUD2, Lentivirus vector, Drug screening, In vitro

田安然, 徐瑞瑞, 胡平平, 李毓雯, 朱传龙. 人EFTUD2基因靶向小分子化合物筛选细胞模型的建立^*[J]. 实用肝脏病杂志, 2021, 24(4): 472-475.

Tian Anran, Xu Ruirui, Hu Pingping, et al. Establishment of a cell model for screening human EFTUD2 gene-targeting small molecule compounds[J]. Journal of Practical Hepatology, 2021, 24(4): 472-475.

参考文献

[1] Zhu C, Xiao F, Lin W. EFTUD2 on innate immunity. Oncotarget, 2015, 6(32):32313-32314.
[2] Zhu C, Xiao F, Hong J, et al. EFTUD2 is a novel innate immune regulator restricting hepatitis C virus infection through the RIG-I/MDA5 pathway. J Virol, 2015, 89(13):6608-6618.
[3] Lyu Z, Wang Z, Luo L, et al. Spliceosome protein EFTUD2 promotes colitis-associated tumorigenesis by modulating inflammatory response of macrophage. Mucosal Immunol, 2019, 12(5):1164-1173.
[4] Tu M, He L, You Y, et al. EFTUD2 maintains the survival of tumor cells and promotes hepatocellular carcinoma progression via the activation of STAT3. Cell Death Dis, 2020, 11(10):830.
[5] Lei L, Yan SY, Yang R, et al. Spliceosomal protein EFTUD2 mutation leads to p53-dependent apoptosis in zebrafish neural progenitors. Nucleic Acids Res, 2017, 45(6):3422-3436.
[6] Wu J, Yang Y, He Y, et al. EFTUD2 gene deficiency disrupts osteoblast maturation and inhibits chondrocyte differentiation via activation of the p53 signaling pathway. Hum Genomics, 2019, 13(1):63.
[7] Huang L, Vanstone MR, Hartley T, et al. Mandibulofacial dysostosis with microcephaly: mutation and database update. Hum Mutat, 2016, 37(2):148-154.
[8] Lehalle D, Wieczorek D, Zechi-Ceide RM, et al. A review of craniofacial disorders caused by spliceosomal defects. Clin Genet, 2015, 88(5):405-415.
[9] Tang L, Covert E, Wilson E, et al. Chronic hepatitis B infection: a review. JAMA, 2018, 319(17):1802-1813.
[10] Yuen MF, Chen DS, Dusheiko GM, et al. Hepatitis B virus infection. Nat Rev Dis Primers, 2018, 4:18035.
[11] Dusheiko G. Will we need novel combinations to cure HBV infection? Liver Int, 2020, 40(Suppl 1):35-42.
[12] Petersen J, Thompson A J, Levrero M. Aiming for cure in HBV and HDV infection. J Hepatol, 2016, 65(4):835-848.
[13] Pierra RC, Dousson CB, Tavis JE. HBV replication inhibitors. Antiviral Res, 2020, 179:104815.
[14] Vigano M, Grossi G, Loglio A, et al. Treatment of hepatitis B: is there still a role for interferon? Liver Int, 2018, 38(Suppl 1):79-83.
[15] Fabrizio P, Laggerbauer B, Lauber J, et al. An evolutionarily conserved U5 snRNP-specific protein is a GTP-binding factor closely related to the ribosomal translocase EF-2. EMBO J, 1997, 16(13):4092-4106.
[16] Frazer LN, Nancollis V, O'Keefe RT. The role of Snu114p during pre-mRNA splicing. Biochem Soc Trans, 2008, 36(Pt 3):551-553.
[17] Bartels C, Urlaub H, Luhrmann R, et al. Mutagenesis suggests several roles of Snu114p in pre-mRNA splicing. J Biol Chem, 2003, 278(30):28324-28334.
[18] Hayes CN, Chayama K. HBV culture and infectious systems. Hepatol Int, 2016, 10(4):559-566.
[19] Torresi J, Tran BM, Christiansen D, et al. HBV-related hepatocarcinogenesis: the role of signalling pathways and innovative ex vivo research models. BMC Cancer, 2019, 19(1):707.
[20] Li F, Wang Z, Hu F, et al. Cell culture models and animal models for HBV study. Adv Exp Med Biol, 2020, 1179:109-135.

人EFTUD2基因靶向小分子化合物筛选细胞模型的建立^*

Establishment of a cell model for screening human EFTUD2 gene-targeting small molecule compounds

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	马艳华, 黄芬, 王文尖. 紫草素对HepG2细胞增殖、凋亡和PI3K/Akt/NF-κB信号通路蛋白表达的影响^*[J]. 实用肝脏病杂志, 2020, 23(4): 471-475.
[2]	庞丽君,石英,郭向华,乔录新,时红林,王珊珊,刘凯. 稳定表达HBx的人肝细胞系7702的建立[J]. 实用肝脏病杂志, 2020, 23(3): 320-323.
[3]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[4]	赵芳芳, 翟永贞, 冯国和. 自体外周血干细胞移植治疗乙型肝炎肝硬化患者疗效及安全性分析[J]. 实用肝脏病杂志, 2019, 22(5): 700-703.
[5]	郭丽平, 张成宏, 宁宝烁, 许敏, 徐贝贝, 王雪, 李异玲. 一种新生大鼠肝细胞分离改良方法的建立^*[J]. 实用肝脏病杂志, 2019, 22(1): 17-20.
[6]	张小三, 张一鸣, 杨树军, 戚春辉, 刘凯, 赵燕. miR-21对HepG2细胞增殖、凋亡和细胞周期的影响^*[J]. 实用肝脏病杂志, 2019, 22(1): 21-24.
[7]	徐溪, 党引利, 吴朔. HCV感染相关干扰素L4真核表达载体的构建与表达[J]. 实用肝脏病杂志, 2018, 21(6): 833-836.
[8]	李俊峰, 郑素军, 刘霜, 任锋, 陈煜, 段钟平. 葡萄糖神经酰胺葡萄糖基转移酶siRNA对7702肝细胞增殖的影响及机制研究^*[J]. 实用肝脏病杂志, 2018, 21(5): 697-700.
[9]	周达, 王晶, 李冰航, 孙超, 陈源文, 范建高. 脯氨酰寡肽酶抑制剂体外对肝星状细胞凋亡、增殖和肝纤维化相关基因表达的影响*[J]. 实用肝脏病杂志, 2018, 21(3): 388-392.
[10]	李文姣, 曹海超, 马澜婧, 张松, 丁美玲, 张浩浩, 聂勇战. 敲减CCAAT/增强子结合蛋白α通过增加O-GlcNAc糖基化水平促进肝癌细胞体外增殖*[J]. 实用肝脏病杂志, 2018, 21(3): 393-396.
[11]	张永婷, 朱传龙, 李军, 章莉莉. c-Met基因过表达脐带间充质干细胞株的构建*[J]. 实用肝脏病杂志, 2018, 21(3): 397-400.
[12]	李兵航，李梦婷，何玲楠，周达，白洁，丁永年，陈源文，范建高. AcSDKP体外抑制脂多糖诱导的小鼠RAW264.7巨噬细胞促炎功能研究*[J]. 实用肝脏病杂志, 2017, 20(2): 142-147.
[13]	张坤，胡海，张圆，刘佳. 大鼠肝星状细胞CTGF、纤维连接蛋白和整合素的表达变化及肝复康的调节作用*[J]. 实用肝脏病杂志, 2017, 20(2): 153-156.
[14]	丰烨，沈洁，过丽莉，李百文，袁广银，宛新建. 涂层和未涂层镁合金材料经体外胆汁浸泡后的变化实验研究*[J]. 实用肝脏病杂志, 2017, 20(2): 211-214.
[15]	仝艳艳, 李光明, 邓怡林, 石翠翠, 黄福德, 范建高. 氧化苯砷体外对大鼠原代肝星状细胞活化的阻抑作用研究^*[J]. 实用肝脏病杂志, 2016, 19(4): 413-417.